E.coli-derived human IKB beta recombinant protein (Position: E56-E237). Human IKB beta shares 82% and 80% amino acid (aa) sequence identity with mouse and rat IKB beta, respectively.
Conjugation:
Unconjugated
Alternative Names:
NF-kappa-B inhibitor beta, NF-kappa-BIB, I-kappa-B-beta, IkB-B, IkB-beta, IkappaBbeta, Thyroid receptor-interacting protein 9, TR-interacting protein 9, TRIP-9, NFKBIB, IKBB, TRIP9
IKB beta/NFKBIB Rabbit Polyclonal Antibody
Clonality:
Polyclonal
Concentration:
Adding 0.2 ml of distilled water will yield a concentration of 500 µg/ml.
Each vial contains antibody formulated with stabilizing components, 0.9 mg NaCl, 0.2 mg Na2HPO4, and 0.05 mg NaN3. *This antibody is supplied in a stabilized formulation. Compatibility with conjugation reactions depends on the chemistry of the conjugation
Form:
Lyophilized
Target:
NF-kappa-B inhibitor beta
Application Dilute:
Western blot, 0.1-0.5µg/ml, Human, Mouse, Rat Immunohistochemistry (Paraffin-embedded Section), 2-5µg/ml, Human
IHC(P) analysis of Human Intestinal Cancer Tissue using Anti-IKB beta Picoband antibody.
Anti-IKB beta Picoband antibody, Western blotting. All lanes: Anti IKB beta at 0.5 ug/ml. Lane 1: Mouse Kidney Tissue Lysate at 50 ug. Lane 2: RH35 Whole Cell Lysate at 40 ug. Lane 3: NRK Whole Cell Lysate at 40 ug. Lane 4: HELA Whole Cell Lysate at 40 ug. Predicted bind size: 38 KD. Observed bind size: 38 KD.
IHC(P) analysis of Mouse Intestine Tissue using Anti-IKB beta Picoband antibody.
Anti-IKB beta Picoband antibody, IHC(P): Human Intestinal Cancer Tissue.
